Alembic Share Price Target 2025, 2026, 2030, 2040, 2050
Alembic Ltd. is one of the oldest and most reputed pharmaceutical companies in India. It was established in 1907 in Vadodara, Gujarat. We specialize in the production and distribution of active pharmaceutical ingredients such as Azithromycin, Venlafaxine, and Telmisartan. The company adheres to strict global quality standards and exports its products worldwide.
This blog will provide the details of Alembic Share Price targets as far as 25 years from now (2025 – 2050) based on its fundamentals, market position, and growth potential.
What is Alembic Ltd NSE: ALEMBICLTD?
Alembic Ltd. specializes in real estate development beyond pharmaceuticals, residential and commercial projects, and power generation through wind turbines and combined heat and power plants. The company generates income through the leasing of commercial real estate and, at the same time, holds significant shares in Pharmaceuticals. With ongoing research projects and future endeavors, the company continues to make progress in various industries.
Fundamental Data
| Metric | Value |
|---|---|
| Market Cap | ₹2,654 Cr. |
| High / Low | ₹169 / ₹78.1 |
| Stock P/E | 8.39 |
| Book Value | ₹87.5 |
| Dividend Yield | 2.35% |
| ROCE (Return on Capital Employed) | 4.81% |
| ROE (Return on Equity) | 12.6% |
| Face Value | ₹2.00 |
| Industry P/E | 29.5 |
| Net Cash Flow (PY) | ₹-0.24 Cr. |
| Profit Before Tax (Annual) | ₹103 Cr. |
| Earnings Per Share (EPS) | ₹12.2 |
| Promoter Holding | 70.9% |
| PEG Ratio | 1.76 |
| Net Profit | ₹314 Cr. |
| Debt | ₹16.2 Cr. |
| Dividend (Last Year) | ₹61.6 Cr. |
| Current Liabilities | ₹131 Cr. |
| Current Assets | ₹200 Cr. |
| 5-Year ROE Variation | -7.43% |
| Debt to Equity Ratio | 0.01 |
| Price to Book Value | 1.18 |
| Graham Number | ₹155 |
Peer Comparisons
| Company | CMP (₹) | P/E | Market Cap (₹ Cr.) | Net Profit (Qtr) (₹ Cr.) | Qtr Profit Var (%) | Sales Qtr (₹ Cr.) | Qtr Sales Var (%) | ROCE (%) |
|---|---|---|---|---|---|---|---|---|
| DLF | 695.50 | 45.88 | 1,72,157.91 | 1,058.73 | 23.19 | 1,528.71 | 0.49 | 5.74 |
| Macrotech Devel. | 1,192.30 | 47.39 | 1,18,913.72 | 944.80 | 61.54 | 4,083.00 | 39.32 | 11.06 |
| Godrej Properties | 2,080.10 | 42.27 | 62,649.22 | 158.20 | 154.05 | 968.88 | 193.21 | 5.74 |
| Oberoi Realty | 1,617.65 | 22.77 | 58,818.17 | 618.38 | 71.70 | 1,411.08 | 33.92 | 15.24 |
| Phoenix Mills | 1,586.85 | 54.94 | 56,731.35 | 352.76 | -8.86 | 975.13 | -1.11 | 12.44 |
| Prestige Estates | 1,258.50 | 93.05 | 54,207.43 | 32.20 | -84.78 | 1,654.50 | -7.87 | 14.86 |
| Brigade Enterprises | 1,029.05 | 39.43 | 25,147.36 | 235.52 | 322.15 | 1,463.94 | 24.72 | 12.66 |
| Alembic Ltd. | 103.35 | 8.39 | 2,653.76 | 65.39 | 6.50 | 57.92 | 47.30 | 4.81 |
| Period | Share Price (INR) |
|---|---|
| Before 1 Year | ₹103.00 |
| Before 6 Months | ₹160.00 |
| Before 5 Years | ₹48.00 |
| All-Time Max | ₹169.00 |
The company specializes in real estate, pharmaceuticals, and energy production. With a substantial promoter stake (70.9%) and low debt, the company’s stability seems assured. With a P/E ratio of 8.39, the stock appears undervalued. The price may fluctuate tomorrow, but the long-term growth potential remains strong.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| Tomorrow | -3.2 from today’s price | +8.8 from today’s price |
ALEMBICLTD Indicator Based Technical Analysis
NOTE!
Signals may differ across timeframes. If you’re planning to purchase ALEMBICLTD and keep it for more than one week, it’s suggested that you choose signals from weekly and daily timeframes. For trading in the short term, signals that range from 5 minutes to 1-hour timeframes are better appropriate.
The company has diversified business in pharmaceuticals, real estate, and power assets. The company’s share price target for 2025 is expected to grow due to strong demand in real estate and API manufacturing. The pharmaceutical sector remains a key revenue driver, ensuring long-term stability and consistent growth in stock value.
Our analysis shows that the share price is expected to be between Rs 75 and Rs 165.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 75 | 165 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 102 | 145 |
| February | 82 | 134 |
| March | 75 | 96 |
| April | 75 | 86 |
| May | 78 | 90 |
| June | 85 | 97 |
| July | 92 | 121 |
| August | 105 | 129 |
| September | 115 | 143 |
| October | 125 | 150 |
| November | 140 | 160 |
| December | 155 | 165 |
The company’s share price could continue to rise until 2026 as real estate projects expand. The company is strengthening its market position through the simultaneous development of residential and commercial areas while the earnings potential of the API segment is increasing. Investors can expect steady returns over time, making an attractive stock for long-term investment.
Our analysis shows that the share price is expected to be between Rs 118 and Rs 198.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2026 | 118 | 198 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 118 | 145 |
| February | 125 | 152 |
| March | 128 | 160 |
| April | 130 | 165 |
| May | 138 | 172 |
| June | 142 | 175 |
| July | 145 | 178 |
| August | 150 | 182 |
| September | 158 | 185 |
| October | 165 | 190 |
| November | 170 | 195 |
| December | 175 | 198 |
The company has its sights set on the thriving Indian real estate market in 2030, as high-end residential projects and commercial rentals will bring profits. Pharmaceutical advancements and new product launches in API manufacturing will support business expansion and position the company for sustainable growth in the stock market.
Our analysis shows that the share price is expected to be between Rs 365 and Rs 475.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2030 | 365 | 475 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 365 | 390 |
| February | 370 | 400 |
| March | 375 | 410 |
| April | 380 | 415 |
| May | 385 | 420 |
| June | 390 | 430 |
| July | 395 | 440 |
| August | 400 | 450 |
| September | 410 | 455 |
| October | 420 | 460 |
| November | 430 | 470 |
| December | 440 | 475 |
The company’s share price could increase significantly in value by 2040 due to its diverse business model. Real estate remains an essential source of income while the pharmaceutical industry is expanding. Energy assets, especially wind energy resources, offer sustainability. Long-term investors could view the company as an attractive long-term investment due to its diverse activities in various industries.
Our analysis shows that the share price is expected to be between Rs 745 and Rs 985.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2040 | 745 | 985 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 745 | 780 |
| February | 755 | 795 |
| March | 770 | 810 |
| April | 780 | 830 |
| May | 800 | 850 |
| June | 820 | 870 |
| July | 830 | 890 |
| August | 850 | 910 |
| September | 870 | 930 |
| October | 890 | 950 |
| November | 910 | 970 |
| December | 940 | 985 |
The company is balanced for robust growth with evolving real estate trends and pharmaceutical innovation in 2050, thanks to continued investment in high-demand sectors and sustainable energy assets such as leases, API production facilities, and sustainable energy assets. These initiatives guarantee the long-term success of the share price and make the company an attractive investment for the future.
Our analysis shows that the share price is expected to be between Rs 1405 and Rs 1965.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2050 | 1405 | 1965 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 1405 | 1480 |
| February | 1440 | 1520 |
| March | 1485 | 1570 |
| April | 1530 | 1625 |
| May | 1580 | 1680 |
| June | 1625 | 1725 |
| July | 1670 | 1780 |
| August | 1720 | 1830 |
| September | 1765 | 1875 |
| October | 1805 | 1905 |
| November | 1850 | 1935 |
| December | 1895 | 1965 |
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 75 | 165 |
| 2026 | 118 | 198 |
| 2030 | 365 | 475 |
| 2040 | 745 | 985 |
| 2050 | 1405 | 1965 |
| Shareholders | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
| Promoters | 70.88% | 70.88% | 70.88% | 70.88% |
| FIIs | 1.78% | 1.97% | 1.42% | 1.07% |
| DIIs | 0.06% | 0.08% | 0.04% | 0.04% |
| Public | 27.27% | 27.07% | 27.66% | 28.02% |
Standard Glass Lining Technology Share Price Target 2025, 2026, 2030, 2040, 2050
Should I Buy Alembic Stock?
The company shareholding reflects strong promoter trust at 70.88%, meaning owners have full belief in their business. At the same time, foreign institutional investors (FIIs) are gradually increasing their holdings from 1.07% in 2024 up to 1.78% by 2024, signifying growing trust in this investment class. Unfortunately, DII holdings have decreased, and thus, the public stake is high at 27.27%. Buy with caution in the long term.
Alembic Ltd Earning Results (Financials)
| Particulars | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | 211 | 157 | 127 | 78 | 74 |
| Expenses | 120 | 101 | 87 | 64 | 62 |
| Operating Profit | 91 | 57 | 40 | 14 | 11 |
| OPM % | 43% | 36% | 32% | 18% | 15% |
| Other Income | 74 | 55 | 54 | 89 | 10 |
| Interest | 2 | 1 | 0 | 0 | 0 |
| Depreciation | 9 | 8 | 7 | 5 | 4 |
| Profit Before Tax | 153 | 103 | 87 | 98 | 17 |
| Tax % | – | 10% | 7% | 12% | 19% |
| Net Profit | 314 | 269 | 191 | 222 | 343 |
| EPS (Rs.) | 12.24 | 10.46 | 7.42 | 8.65 | 13.35 |
| Dividend Payout % | – | 23% | 30% | 21% | 2% |
Expert Forecasts On The Future Of Alembic Ltd.
The company finances show steady growth with rising sales, profits, and operating margins, as well as increasing earnings per share (EPS). The dividend payout remains secure. Analysts forecast long-term growth potential based on the company’s solid history and performance. If fundamentals stay strong, So It can be a good investment for the future. Always invest wisely!
Is Alembic Stock Good to Buy? (Bull case & Bear case)
Bullish Case:
- Strong earnings growth & rising EPS
- Stable dividend payments
- Improved operating margins & efficiency
- Strong industry presence & long-term potential
Bearish Case:
- Fluctuating net profits
- Competition & regulatory risks
- Impact of market volatility
Conclusion
Alembic Pharma has an established business with pharmaceutical APIs. In addition, the company has residential and commercial projects as well as investments in the energy sector. Alembic’s long-term growth prospects and strong fundamentals make the company an attractive long-term bet. In the short term, however, market volatility could affect the share’s performance. If you’re considering an investment, you should read the full article for details about the company’s performance and future stock projections.
Dr Agarwal Healthcare Share Price Target 2025, 2026, 2030, 2040, 2050
